Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) – Pipeline Review, H2 2016’, provides in depth analysis on Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted pipeline therapeutics.

The report provides comprehensive information on the Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA)

The report reviews Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics and enlists all their major and minor projects

The report assesses Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Inovio Pharmaceuticals, Inc.

Lipotek Pty Ltd.

Polymun Scientific Immunbiologische Forschung GmbH

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) Overview 6

Therapeutics Development 7

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Stage of Development 7

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Therapy Area 8

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Indication 9

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Companies 12

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Universities/Institutes 14

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Companies Involved in Therapeutics Development 21

Inovio Pharmaceuticals, Inc. 21

Lipotek Pty Ltd. 22

Polymun Scientific Immunbiologische Forschung GmbH 23

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Drug Profiles 24

HG856-A - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

HG856-BCG - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

HG856-SeV - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

RSQ-15 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

SSIH-56IC31 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

TB/FLU-04L - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

tuberculosis vaccine - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

tuberculosis vaccine - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Featured News & Press Releases 33

Nov 08, 2013: Valneva: SSI and Aeras initiate Phase I/IIa Clinical Trial for Tuberculosis Vaccine Candidate Using IC31 Adjuvant 33

Jan 11, 2012: Intercell And Statens Serum Institut Progress Vaccine Clinical Development To Fight Tuberculosis 34

Dec 01, 2011: Vaccine Targeting Latent Tuberculosis Enters Clinical Testing 34

Jan 24, 2011: Researchers At Statens Serum Institut Develop New Vaccine With Dual Protection Against Tuberculosis 35

Jan 24, 2011: Researchers Develop New Vaccine With Dual Protection Against Tuberculosis 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 21

Pipeline by Lipotek Pty Ltd., H2 2016 22

Pipeline by Polymun Scientific Immunbiologische Forschung GmbH, H2 2016 23

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Routes of Administration, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared